Indeed, dual knockdown of BCL-2 and BCL-xL increased sensitivity of PI3K/AKT/mTOR inhibition in human AML cell lines and knockdown of AKT, on this end, increased lethality of the BCL-2/-xL inhibitor ABT-737. The gene discussed is PIK3CA; the disease is acute myeloid leukemia.